
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 16, 2026, 5:09 AM ET
Roth Capital raised its Capricor price target to $10.50 from $7 with a Neutral rating, while Oppenheimer kept Outperform and a $54 target ahead of the November 22 Deramiocel FDA decision.
Nasdaq: $CAPRDeramiocel · Duchenne muscular dystrophyRefined upper-limb indicationBinary regulatory risk
CAPR Stock Hub: Capricor Therapeutics News, Deramiocel and FDA Review
Capricor’s deramiocel application has a November 22, 2026 FDA target action date following a major amendment. The refined proposed indication focuses on upper limb function, distinct from the cardiomyopathy question on which an advisory committee voted 9–3 against effectiveness in July. Statistical interpretation, open-label evidence and the final label remain central uncertainties. On November 10, 2026 the company reported about $198.5 million in cash, restricted cash and marketable securities at September 30, 2026, against $96.4 million nine-month operating cash use, and disclosed a Form 483 with one observation from the FDA’s July clinical-trial inspection.
Research Library
The complete CAPR research report
74 pages · Research updated November 10, 2026 · Dated snapshot
FDA target action date · company disclosure
Deramiocel FDA review · November 22, 2026
The August 24 disclosure says the major amendment contains 24-month HOPE-3 open-label extension data and additional analyses supporting a refined upper-limb indication. A target date is not an assurance of approval, a particular label or an on-time outcome. Company announcement filed with SEC →
Latest company update: on November 10, 2026, after the market close, Capricor reported third-quarter results and held its conference call and webcast at 4:30 p.m. ET. The release confirms the November 22 target action date and states that the FDA’s July 2026 Bioresearch Monitoring inspection ended with a Form 483 containing one observation; the company has submitted its response and is awaiting FDA feedback (results release filed with SEC). Follow official FDA and company disclosures; the July advisory vote concerned effectiveness in DMD cardiomyopathy and was non-binding.
CAPR daily chart
CAPR stock: dated key data
Chart analysis · JC
Technical chart analysis of $CAPR with bull and bear scenarios on JC Just Charts.
Cash and securities
$198.5M
September 30, 2026; cash, cash equivalents, restricted cash and marketable securities.
Q3 net loss
$42.7M
Quarter ended September 30, 2026; $0.73 per share.
9M operating cash use
$96.4M
Nine months ended September 30, 2026; $96.428M in the filing.
Common shares
58.142M
58,142,114 outstanding at November 9, 2026.
Advisory committee vote
3–9–0
July 29, 2026; for/against/abstain on effectiveness in DMD cardiomyopathy. Non-binding.
Short interest
18.765M
October 30, 2026 settlement; 18,765,089 shares and 7.38 days to cover.
Financial and share data: September 30 Form 10-Q; dated price and short interest: Nasdaq historical prices and short interest.
Where Capricor stands now
The application’s proposed indication and evidentiary basis have evolved. The July advisory discussion centered on cardiomyopathy, while the major amendment seeks a refined upper-limb indication. Company analyses and the FDA briefing use different statistical-plan interpretations, so the results should not be compressed into a single undisputed efficacy claim.
The company’s official investor calendar provides the October 7 PPMD webinar presentation on HOPE-3 extension data. The presentation supplies company context alongside the separately published FDA assessment. Official webinar page →
The third-quarter release of November 10, 2026 adds dated facts ahead of the decision. Total operating expenses were about $44.7 million in the quarter, against $26.3 million a year earlier, driven mainly by pre-commercial activities and manufacturing scale-up; the net loss was about $42.7 million, or $0.73 per share, and no revenue was recognized. A workforce reduction of about 10% of employees was implemented in the quarter. The company says the San Diego GMP facility is positioned to support an initial commercial launch if deramiocel is approved, has begun regulatory engagement in Europe and Japan, and expects the arbitration hearing with Nippon Shinyaku and NS Pharma to begin in mid-2027. Chief Executive Officer Linda Marbán said the company remains confident in the strength of its data; that is the company’s position, not an indication of the FDA’s decision. Q3 release →
Main risk: The FDA must decide whether the submitted evidence supports an approvable indication. A negative prior advisory vote, statistical restatement, absence of a concurrent placebo comparator in extension data and commercial-partner disputes remain separate risks.
Constructive case
The company’s upper-limb analysis and longer follow-up provide evidence for the amended submission. Acceptance of a sufficiently supported narrower indication could establish a development path, while the September 30 reserve of about $198.5 million, with no ATM sales in 2026 through November 10, provides a cushion. These are conditional possibilities, not approval predictions.
Cautious case
The FDA may interpret the statistical record differently or require further evidence. Open-label comparisons cannot replace a concurrent randomized comparison. A further regulatory setback would affect commercialization, spending, partner arrangements and the lease contingency, while third-quarter operating expenses had already risen to about $44.7 million.
CAPR stock news: six latest updates
Nov 16, 2026
Roth lifts Capricor price target to $10.50, Oppenheimer holds $54 ahead of FDA decision
Roth Capital raised its Capricor price target to $10.50 from $7 and kept a Neutral rating, assigning a 25% chance of Deramiocel approval by November 22. Oppenheimer maintained an Outperform rating and $54 price target. The FDA rejected Deramiocel in July 2025, and an advisory committee voted 9-3 against the evidence for DMD-related cardiomyopathy in July. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Nov 15, 2026
Capricor's Deramiocel FDA decision for Duchenne upper limb impairment due Nov. 22
Capricor awaits an FDA decision on Nov. 22 for Deramiocel in upper limb impairment in Duchenne patients older than nine, after the review was extended from Aug. 22. The FDA issued a complete response letter in July 2025, and in July an advisory panel voted 9-3 against the evidence of effectiveness for Duchenne-related heart disease. Capricor says Hope-3 met its main goal and its San Diego facility is ready to support an initial launch. Not confirmed by a company release or filing at the time of writing; to be verified.
Nov 13, 2026
Roth Capital lifts Capricor price target to $10.50 from $7
Roth Capital raised its price target on Capricor Therapeutics to $10.50 from $7. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Nov 11, 2026
Jones Trading raises Capricor rating from Hold, sets $25 target
Jones Trading upgraded its rating on Capricor Therapeutics from Hold. The bank set a price target of $25. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Nov 10, 2026
Capricor says deramiocel BLA in final review as Nov. 22 FDA action date nears
On its third-quarter call, CEO Linda Marbán said the deramiocel Biologics License Application is in final review ahead of the FDA's Nov. 22 target action date. Capricor is preparing for launch and pursuing independent commercialization during an ongoing arbitration with NS Pharma. Its San Diego facility can support roughly 250 patients annually, with an expansion targeted for validation in the first half of 2027 to support 2,000–2,500 patients. Cash was about $198.5 million as of September 30. Reported by the press from an official company announcement; the primary document was not yet available in our sources at the time of writing.
Nov 10, 2026
Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Capricor reported a net loss of approximately $42.7 million, or $0.73 per share, for the third quarter of 2026, compared to approximately $24.6 million, or $0.54 per share, for the third quarter of 2025. Cash, cash equivalents, restricted cash and marketable securities totaled approximately $198.5 million as of September 30, 2026. The BLA for Deramiocel for Duchenne muscular dystrophy has a PDUFA target action date of November 22, 2026.
CAPR stock catalysts: dated milestones
- November 10, 2026 · Q3 results and conference call, 4:30 p.m. ETCompleted
Results for the quarter ended September 30, 2026 were released after the market close and discussed on the conference call and webcast: about $198.5 million in cash, restricted cash and marketable securities, a $42.7 million quarterly net loss, the November 22 target date confirmed and a Form 483 response awaiting FDA feedback. Q3 release · Announcement of November 3.
- November 22, 2026 · Deramiocel target action dateCompany-disclosed FDA target
Review of the major amendment and refined proposed indication; neither approval nor timing is guaranteed.
- First half of 2027 · Cleanroom expansion validationCompany target
Validation of the second-floor cleanroom expansion at the San Diego facility is targeted for the first half of 2027, according to the November 10 release.
- Mid-2027 · Arbitration hearing with Nippon Shinyaku and NS PharmaCompany expectation
The company expects the arbitration hearing on the deramiocel distribution agreement to commence in mid-2027.
- December 31, 2026 · Lease approval contingencyDisclosed contractual condition
The September 30, 2026 Form 10-Q states that either party may terminate the new headquarters lease if FDA approval of deramiocel on terms acceptable to the company is not received on or before this date, and that the lease term will be reassessed if the contingency is not resolved by then. It is not a projected cash payment or an assumed approval date.
HOPE-3 evidence: keep the analyses distinct
Randomized trial
Upper-limb interpretation
Capricor reports a positive primary analysis. The FDA briefing evaluates earlier statistical-plan specifications differently. A company efficacy claim and a regulator’s assessment must remain separately attributed.
Cardiac secondary endpoint
Statistical restatement
The company restated the key LVEF endpoint from p=0.04 to p=0.09. Endpoints below a failed hierarchical test are not automatically protected against Type I error.
Open-label extension
Longer follow-up, different comparator
The delayed-start analysis compares patients with their own prior year. It does not provide a concurrent placebo-controlled comparison during the extension.
FDA briefing document · Company statistical update · Extension release.
CAPR cash, dilution and commercial obligations
The September 30, 2026 reserve of about $198.5M, including restricted cash, must be read alongside $96.4M nine-month operating cash use, total liabilities of about $120.6M (largely lease obligations for the new headquarters and manufacturing facility) and future development or launch costs. The August release replaced the earlier dated runway guidance with an at-least-twelve-month statement, which the November 10 release repeats; the company said it would give longer-term guidance after greater regulatory clarity, and that it sold no shares under its at-the-market program from January 1 through November 10, 2026.
Unused financing capacity, outstanding securities and equity-plan capacity are different from issued common shares. The filing also describes commercial-partner proceedings and an approval-related lease contingency. A regulatory outcome can therefore affect more than the clinical program.
Merlintrader Health Score · CAPR
2.9out of 5
Reassessed November 10, 2026 after the third-quarter results; scores unchanged from the October 26, 2026 assessment. The five weighted pillars total 2.85/5, displayed as 2.9 after rounding to one decimal. The score describes financial and operational robustness, not a valuation, price target or recommendation.
CAPR red flags
- Binary FDA review risk and possible changes to the proposed label or timing.
- A Form 483 with one observation from the July 2026 clinical-trial inspection; the company’s response was awaiting FDA feedback as of November 10, 2026.
- Different statistical-plan interpretations and the restated cardiac endpoint.
- Open-label extension comparisons are not concurrent randomized placebo comparisons.
- Cash consumption, future financing and dilution.
- Commercial-partner proceedings and approval-related lease obligations.
- High dated short interest can amplify volatility without predicting direction.
CAPR Stock FAQ: Capricor Therapeutics Questions Answered
What is Capricor’s deramiocel PDUFA date?
Capricor’s August 24, 2026 announcement sets November 22, 2026 as deramiocel’s FDA target action date following a major amendment. The refined proposed indication focuses on upper-limb function in Duchenne muscular dystrophy. A target date does not guarantee approval, a particular label or an on-time decision. Details.
Is Capricor’s deramiocel FDA approved?
As of November 10, 2026, Capricor’s deramiocel remains under FDA review rather than approved, with the November 22 target date confirmed in the third-quarter release. The major amendment includes 24-month HOPE-3 open-label extension data and additional analyses supporting a refined proposed upper-limb indication in Duchenne muscular dystrophy. Details.
How much cash does Capricor have, and how long will it last?
Capricor reported about $198.5 million in cash, cash equivalents, restricted cash and marketable securities at September 30, 2026, against $96.428 million nine-month operating cash use, and says its resources are sufficient for at least the next twelve months. Spending, regulatory requirements and commercialization plans affect future funding needs. Details.
Is CAPR stock at risk of dilution?
Yes: Capricor’s September 30, 2026 quarterly filing describes an at-the-market program and equity awards, while outstanding common shares were 58,142,114 at November 9. The company sold no ATM shares from January 1 through November 10, 2026, but further capital raising or award exercises can dilute existing holders; that dated count is not a current fully diluted share total. Details.
When does Capricor report earnings?
Capricor released results for the third quarter ended September 30, 2026 after the market close on Tuesday, November 10, 2026, and management hosted a conference call and webcast at 4:30 p.m. ET that day. As of November 10, 2026, the company had not announced the date of its next quarterly report. The November 22 deramiocel target action date is a regulatory milestone, separate from the earnings schedule. Details.
What does Capricor Therapeutics do?
Capricor Therapeutics develops cell and exosome-based therapies. Its lead candidate, the cell therapy deramiocel for Duchenne muscular dystrophy, is under FDA review with a November 22, 2026 target action date, while its exosome-based programs are at an earlier stage of development. Details.
What did the FDA advisory committee vote mean for Capricor?
The July 29, 2026 advisory vote concerned deramiocel’s effectiveness in DMD cardiomyopathy, with nine votes against and three in favor. It was non-binding and preceded Capricor’s refined upper-limb amendment; the two proposed indications and their evidence must be distinguished. Details. Supporting document.
Does Capricor’s 76% HOPE-3 extension figure compare against placebo?
No: Capricor’s October 5, 2026 extension announcement compares the delayed-start group’s treated year with its own prior placebo year. There was no concurrent placebo arm in that comparison, so the 76% figure differs from a randomized concurrent treatment-versus-placebo result. Details.
Primary sources
- November 10, 2026 · Q3 2026 financial results and corporate update (Form 8-K, Exhibit 99.1)
- November 10, 2026 · Form 10-Q for the quarter ended September 30, 2026
- November 3 announcement: Q3 results and conference call on November 10
- June 30 Form 10-Q
- August 24 major-amendment disclosure
- August 13 results and statistical update
- FDA briefing document
- Official October 7 webinar page
- October 5 extension results
- Millennium Schedule 13G/A
- Official company press releases
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $CAPR or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms and conditions pages.



